Baidu
map

如何写好文章的“介绍信”—Cover Letter?

2022-06-06 梅斯学术 MedSci原创

文章能否送审,Cover Letter有一半的功过,面对掌握文章生杀大权的编辑,我们要竭尽全力写好Cover Letter,毕竟送不送审就在编辑的一念之间。

很多科研工作者都投过SCI文章,在经历了无数个废寝忘食地查阅文献,披星戴月地久久挣扎于实验的苦海后,写就的SCI文章像是自己的“孩子”,凝聚了科研工作者太多的辛酸与苦楚。

然而,很多情况下作者认为所投期刊比较适合自己的文章,但现实往往是文章还未外审,就被拒稿。究其原因,可能是CoverLetter没有写好,不够吸睛,没有为编辑留下深刻的第一印象。为此,小编吸取宝贵的经验教训整理了些资料,供大家参考。

 

一、究竟什么是CoverLetter呢?

Cover Letter,它是一种非常务实的文体,往往伴随着其他材料出现,其作用就是介绍其他材料的用处和目的,像一封“介绍信”。

好的CoverLetter可以帮助编辑快速了解文章的内容,并成功搭建起Editor与Reviewer之间的桥梁,避免编辑直接拒稿,更有利于投稿人的稿件被善待。

 

二、如何写一封让人“过目不忘”的CoverLetter?

CoverLetter一般包括以下几个部分:

①期刊编辑的姓名(不知道编辑是谁的情况下直接用Deareditor或DearProfessor);

②投稿文章的标题(全名)

③提交期刊/目标期刊的名称

④投稿文章的类型publication type (letter, communications,original research article, review, comments)

⑤文章简介:此部分是核心内容,主要包括:为什么做这项研究,即研究背景和目的(Backgroudand Aims);研究有什么重要创新和发现(Results)?表明了什么(Conclusion)?读者感兴趣吗?这项研究与期刊宗旨&范围契合吗(Aims&Scope)?在这里,投稿人要用最简短的语言把文章的亮点(Highlights)展现出来,阐明研究的影响力,抓住编辑兴趣,更重要的是,一定要让编辑认为该文章适合在本期刊发表,符合期刊主题,避免因主题不符等原因被拒稿。

⑥声明:无一稿多投,以及作者无利益冲突,要说明投稿文章的专一性,以及所有署名作者对自己的排名顺序,并对此论文内容有所了解,避免后续可能存在的争议和冲突,以表示虚心接受Reviewer对文章的评判,并真诚希望发表。

⑦作者信息:一般为通讯作者姓名,所属机构,通讯地址,联系电话,邮箱等。

 

CoverLetter的具体写作示例

以下是泰勒&弗朗西斯(Talyor&Francis)出版社给出的CoverLetter模板,供参考:

 

图片

图片来源于网络

常用示例一:

Dear editor:

We submit hereby the manuscript entitled: “XXX”. All authorshave read this manuscript and would like to have it considered exclusively forpublication in [XXX Journal name]. None of the material related to thismanuscript has been published or is under consideration for publicationelsewhere, including the internet. We submit this manuscript based on thefollowing reasons:

1. Background and Significance:....

2. Originality andNovelties:.......

3. ExtensiveInterests:........

We would be very grateful if the submitted manuscript couldbe reviewed and considered for publication in Advanced Functional Materials.Everything goes well!!

Your kindconsiderations will be greatly appreciated.

With best regards,

Sincerely Yours,

Correspondingauthor

Corresspondingaddress

Date

 

常用示例二:

Dear Prof. XX:

This is a manuscript by ** and ** entitled “.......”. It issubmitted to be considered for publication as a “...” in your journal. Thispaper is new. Neither the entire paper nor any part of its content has beenpublished or has been accepted elsewhere. It is not being submitted to anyother journal.

We believe the paper may be of particular interest to thereaders of your journal as it ........

Correspondenceshould be addressed to ** at the following address, phone and fax number, andemail address:

...

Thanks very muchfor your attention to our paper.

Sincerely yours,

Your name

 

常用示例三:

Dear Dr. name:

We submit our manuscript entitled “文章title” to 杂志名 for publication.

简单介绍文章的主要创新点和意义,不易过多,但要突出新意和关键点。

All authors have seen themanuscript and approved to submit to your journal.

Thank you very much for yourattention and consideration.

Sincerely yours,

通讯作者

 

三、Cover Letter的写作注意事项

Cover Letter的整体用词和语气要谦逊、真诚,表示尊敬,信末记得也要礼貌感谢一下编辑,具体注意事项如下:

1) 认真对待 Cover Letter,第一印象会持续很久或者你永远也不会再有机会重塑第一印象;

2) 投稿之前一定要核对主编的姓名和称谓,以及文章题目和期刊名称,张冠李戴是大忌;

3) Cover Letter不是摘要,千万不要直接copy摘要,要用自己的语言精炼的把要点概括出来;

4) 不要夸大其词,影响和意义不可胡吹乱造,主编审稿无数,会一眼看出;

5) 用词简单、保持谦虚,华丽的辞藻和高端的语句没有多大的意义,语言简洁、通俗、内敛反而能让人眼前一亮;

6) 联系人邮箱用带有单位后缀的邮箱,尽量不要用个人邮箱,特别是「qq.com」;

7) 语法正确,一定不要有拼写错误,这会使编辑和审稿人对该文章的印象大打折扣,一般润色机构可以免费润色Cover Letter,因此润色手稿时可以一并上传。

8) 写完认真检查每处细节。

 

以上就是对Cover Letter的详细介绍。

文章能否送审,Cover Letter有一半的功过,面对掌握文章生杀大权的编辑,我们要竭尽全力写好Cover Letter,毕竟送不送审就在编辑的一念之间。

最后,预祝大家投稿即中,马到成功,Paper多多。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2127826, encodeId=c229212e826d2, content=感谢分享!非常有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d08643505, createdName=ms7000001428685349, createdTime=Sun Apr 23 14:15:16 CST 2023, time=2023-04-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1783737, encodeId=a40d1e83737da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 10 19:12:12 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038426, encodeId=ed2720384265e, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Mar 12 15:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077593, encodeId=3cbb20e759392, content=<a href='/topic/show?id=864f51315b' target=_blank style='color:#2F92EE;'>#cover letter#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5131, encryptionId=864f51315b, topicName=cover letter)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Mar 12 02:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224881, encodeId=6b52122488168, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Jun 07 06:50:32 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224790, encodeId=a8a41224e90d6, content=第一次接触,需要进一步学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/7d86fb2c92182c7534550d2c58260760.jpg, createdBy=dd3e2288139, createdName=何以笙箫, createdTime=Mon Jun 06 18:53:20 CST 2022, time=2022-06-06, status=1, ipAttribution=)]
    2023-04-23 ms7000001428685349 来自北京

    感谢分享!非常有帮助!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2127826, encodeId=c229212e826d2, content=感谢分享!非常有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d08643505, createdName=ms7000001428685349, createdTime=Sun Apr 23 14:15:16 CST 2023, time=2023-04-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1783737, encodeId=a40d1e83737da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 10 19:12:12 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038426, encodeId=ed2720384265e, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Mar 12 15:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077593, encodeId=3cbb20e759392, content=<a href='/topic/show?id=864f51315b' target=_blank style='color:#2F92EE;'>#cover letter#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5131, encryptionId=864f51315b, topicName=cover letter)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Mar 12 02:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224881, encodeId=6b52122488168, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Jun 07 06:50:32 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224790, encodeId=a8a41224e90d6, content=第一次接触,需要进一步学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/7d86fb2c92182c7534550d2c58260760.jpg, createdBy=dd3e2288139, createdName=何以笙箫, createdTime=Mon Jun 06 18:53:20 CST 2022, time=2022-06-06, status=1, ipAttribution=)]
    2022-07-10 yahu
  3. [GetPortalCommentsPageByObjectIdResponse(id=2127826, encodeId=c229212e826d2, content=感谢分享!非常有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d08643505, createdName=ms7000001428685349, createdTime=Sun Apr 23 14:15:16 CST 2023, time=2023-04-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1783737, encodeId=a40d1e83737da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 10 19:12:12 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038426, encodeId=ed2720384265e, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Mar 12 15:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077593, encodeId=3cbb20e759392, content=<a href='/topic/show?id=864f51315b' target=_blank style='color:#2F92EE;'>#cover letter#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5131, encryptionId=864f51315b, topicName=cover letter)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Mar 12 02:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224881, encodeId=6b52122488168, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Jun 07 06:50:32 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224790, encodeId=a8a41224e90d6, content=第一次接触,需要进一步学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/7d86fb2c92182c7534550d2c58260760.jpg, createdBy=dd3e2288139, createdName=何以笙箫, createdTime=Mon Jun 06 18:53:20 CST 2022, time=2022-06-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2127826, encodeId=c229212e826d2, content=感谢分享!非常有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d08643505, createdName=ms7000001428685349, createdTime=Sun Apr 23 14:15:16 CST 2023, time=2023-04-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1783737, encodeId=a40d1e83737da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 10 19:12:12 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038426, encodeId=ed2720384265e, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Mar 12 15:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077593, encodeId=3cbb20e759392, content=<a href='/topic/show?id=864f51315b' target=_blank style='color:#2F92EE;'>#cover letter#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5131, encryptionId=864f51315b, topicName=cover letter)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Mar 12 02:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224881, encodeId=6b52122488168, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Jun 07 06:50:32 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224790, encodeId=a8a41224e90d6, content=第一次接触,需要进一步学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/7d86fb2c92182c7534550d2c58260760.jpg, createdBy=dd3e2288139, createdName=何以笙箫, createdTime=Mon Jun 06 18:53:20 CST 2022, time=2022-06-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2127826, encodeId=c229212e826d2, content=感谢分享!非常有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d08643505, createdName=ms7000001428685349, createdTime=Sun Apr 23 14:15:16 CST 2023, time=2023-04-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1783737, encodeId=a40d1e83737da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 10 19:12:12 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038426, encodeId=ed2720384265e, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Mar 12 15:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077593, encodeId=3cbb20e759392, content=<a href='/topic/show?id=864f51315b' target=_blank style='color:#2F92EE;'>#cover letter#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5131, encryptionId=864f51315b, topicName=cover letter)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Mar 12 02:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224881, encodeId=6b52122488168, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Jun 07 06:50:32 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224790, encodeId=a8a41224e90d6, content=第一次接触,需要进一步学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/7d86fb2c92182c7534550d2c58260760.jpg, createdBy=dd3e2288139, createdName=何以笙箫, createdTime=Mon Jun 06 18:53:20 CST 2022, time=2022-06-06, status=1, ipAttribution=)]
    2022-06-07 学医无涯

    学习一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2127826, encodeId=c229212e826d2, content=感谢分享!非常有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9d08643505, createdName=ms7000001428685349, createdTime=Sun Apr 23 14:15:16 CST 2023, time=2023-04-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1783737, encodeId=a40d1e83737da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jul 10 19:12:12 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038426, encodeId=ed2720384265e, content=<a href='/topic/show?id=f7c61e90472' target=_blank style='color:#2F92EE;'>#TTE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17904, encryptionId=f7c61e90472, topicName=TTE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Mar 12 15:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077593, encodeId=3cbb20e759392, content=<a href='/topic/show?id=864f51315b' target=_blank style='color:#2F92EE;'>#cover letter#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5131, encryptionId=864f51315b, topicName=cover letter)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sun Mar 12 02:12:12 CST 2023, time=2023-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224881, encodeId=6b52122488168, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue Jun 07 06:50:32 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224790, encodeId=a8a41224e90d6, content=第一次接触,需要进一步学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/11/7d86fb2c92182c7534550d2c58260760.jpg, createdBy=dd3e2288139, createdName=何以笙箫, createdTime=Mon Jun 06 18:53:20 CST 2022, time=2022-06-06, status=1, ipAttribution=)]
    2022-06-06 何以笙箫

    第一次接触,需要进一步学习

    0

相关资讯

COVER LETTER(投稿信)实用指南并附样文

1、 什么是cover letter?指的是投稿信2、cover letter的内容主要包括那些?应该简述所投稿件的核心内容、主要发现和意义,拟投期刊,对稿件处理有无特殊要求等(如“not to review” list)。另外,请附上主要作者的中文姓名、通讯地址、电话、传真和e-mail地址。此外有的杂志要求推荐几位审稿人及其联系方式。以及谁已经阅读过该文(当然是牛人)。我投的那个杂志是要求说明

投稿时经常碰到的一些英文表达

1. Cover Letter 投稿信,一般包括一段文字,说明文章的重要性2. Submitted to Journal 刚提交的状态3. Manuscript received by Editorial Office 或者Notification of Manuscript Receipt就是你的文章到了编辑手里了,证明投稿成功4. With editor如果在投稿的时候没有要求选择编辑,就先到

英文SCI论文写作、投稿过程中的注意事项

【写作前准备】 1、自己的实验结果是否够发一篇SCI文章? 2、适合发表在什么杂志?是选择专业期刊?还是综合期刊? 3、为什么类型的投稿(Types of submission)?比如Articles(论著);Reviews(综述);Reports(报告);Letter to editor(来信)等。 4、该杂志的影响因子(Impact factor)是多少,每年发表多少文章?是否有过本土中国人在

用审稿人的角度看SCI写作关键十大要点

本篇稿件是我们根据大量投稿文章,以及与许多杂志编辑交流的心得,并结合网站上相关的观点总结而成,供大家参考。 从审稿人的角度看,一片文章的命运往往在审稿人打开它的一瞬间就决定了。一个熟练的审稿人会在接到文章后用几分钟的时间通读一遍,从而对作者和文章的情况有一个初步的判断。在这里,审稿人最喜欢两个极端:一是通篇充满了细节上的

如何向SCI杂志投稿?

目前,绝大多数大医院的医生晋升高级职称时需有SCI检索的论著,因此如何向SCI杂志投稿是临床医生最为关注的。以下由韩济生院士的演讲内容,进行了一些整理。同时,m.capotfarm.com进行了一定的补充和完善,尤其是投稿中的一些小经验,供大家参考。 一、什么是SCI杂志? SCI即“Science Citation Index”的缩写,中文意思是

SCI文章投稿经验技巧(MedSci)

SCI论文的关键点 SCI文章对于我们每个人来说,都非常重要。那么一篇文章能不能发表SCI杂志,有哪些关键点?MedSci总结有几个关键性环节: 1、首先当然是文章的设计,MedSci编辑经常发现作者递送过来的文章一个重要的问题就是设计存在缺陷,不是分组缺少,就是样本量过低,或缺少对照,或各部分实验逻辑性不强,这些致命性缺陷是困扰许多作者的关键问题。 2

Baidu
map
Baidu
map
Baidu
map